WTI crude jumps 1.8% to $92.16 as Murban premium hits $19

source:

[1] WTI November crude oil futures settle up $1.64, or 1.81%, at $92.16/barrel (https://wallstreetcn.com/livenews/3169819 ...)[2] Oil Falls as Mideast Developments Remain in Focus (https://www.msn.com/en-us/news/other/oil-fall ...)[3] Belgi 4: Bestemming bereikt (https://www.wieringernieuws.nl/index.php?pagi ...)

Related News

Sep 23 2026, 19:27

Rosen probes Anavex over disclosures tied to CEO's for-cause exit

Rosen Law Firm said it is investigating potential securities claims against Anavex Life Sciences Corp. (NASDAQ: AVXL) over allegations the company issued materially misleading business information, four months after the biotech's board fired its chief executive for cause. The New York-based plaintiffs' firm, which says it has recovered billions of dollars for investors and was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017, is preparing a class action and is soliciting shareholders who bought Anavex securities. "If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement," the firm said in its Sept. 21 notice, which directs investors to contact Phillip Kim, Esq. at 866-767-3653. The investigation traces to a Form 8-K Anavex filed with the SEC on May 6, 2026. In that filing, a special committee of the board said it had "terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause," effective immediately, "for, among other things, conduct that the Special Committee believed was inconsistent with Company policy." The committee also asked Missling to resign from the board. Anavex has not disclosed the specific conduct at issue, and the company did not immediately respond to a request for comment on the Rosen notice. Rosen's notice does not name a class period, a proposed lead plaintiff, or a damages figure, and no complaint has been filed. Under the Private Securities Litigation Reform Act, a lead-plaintiff motion is typically due within 60 days of the first published notice — a window that, measured from the Sept. 21 announcement, would close in late November 2026. The firm's economics are contingency-based: shareholders pay no upfront fees, and counsel recovers a percentage of any settlement or judgment, typically 20% to 33% of the recovery after court approval. The disclosure gap is the crux. A for-cause termination tied to conduct "inconsistent with Company policy" raises the question of what the board knew and when it knew it, and whether earlier statements about Missling's leadership or Anavex's clinical programs were accurate when made. Anavex's lead asset, blarcamesine (Anavex 2-73), is an oral sigma-1 receptor agonist in development for Alzheimer's disease and Parkinson's disease; the company has reported Phase 2b/3 data in Alzheimer's and is pursuing regulatory pathways in multiple jurisdictions. Any litigation that forces disclosure of internal communications around those programs carries reputational weight beyond the legal cost. For holders, the near-term risk is a two-track overhang: legal expense and management distraction on one side, and the unresolved question of why the board acted on the other. Anavex has not disclosed a successor CEO, a restated financial, or an amended 8-K expanding on the special committee's findings. Those three items — plus any lead-plaintiff filing in federal court — are the events that will determine whether this stays a law-firm notice or becomes a docketed case with a defined damages claim. Peer context matters for scale. Securities class actions against small- and mid-cap biotechs are common after abrupt executive departures, and most settle rather than reach trial; the median settlement in such cases runs in the low single-digit millions of dollars, a fraction of the headline losses alleged. That math matters for a company of Anavex's size, where defense costs alone can consume a meaningful share of cash reserves before any settlement is reached. The stock's reaction to the Rosen announcement was not disclosed in the firm's notice, and Anavex has not commented on the investigation. Investors will watch for an amended 8-K or a formal complaint, either of which would convert an open inquiry into a dated legal proceeding. This article is for informational purposes only and does not constitute investment advice.

Sep 23 2026, 19:11

Silver falls 4% to $64.47 as UBS holds $80 target

Spot silver slid 4% to $64.47 an ounce on Sept. 23, 2026, its steepest one-day decline of the current advance, even as UBS held a price target roughly 24% above that level. The Swiss bank's $80/oz call rests on two demand pillars it says operate independently of the daily tape: investors buying the metal as a hedge against fiscal deterioration, and industrial spending on electrification. UBS strategists Wayne Gordon and Dominic Schnider set the path on Aug. 29, 2026 and reaffirmed it twice in September, according to the bank's published outlook. The full trajectory runs $70/oz by December 2026, $75/oz by March 2027, $75/oz by June 2027 and $80/oz by September 2027. Those figures sit well below where UBS stood earlier in 2026, when it carried $95/oz to $100/oz targets. In May 2026 the bank cut its 2026 silver supply-deficit estimate by about 80%, from roughly 300 million ounces to 60-70 million ounces, removing the physical-scarcity pillar that had justified the higher numbers. That revision history matters for how the current target should be read. The $80/oz September 2027 figure is a moderated bull case leaning on monetary debasement and resilient industrial offtake, not on a tight physical market. UBS itself flags four conditions that "could interrupt the advance": industrial substitution away from silver at elevated prices, weaker global growth suppressing solar and electronics demand, a more hawkish Federal Reserve, and an unwind of crowded long futures positions. Silver's dual identity explains the volatility. UBS describes the metal as a high-beta equivalent of gold — it moves in the same direction but with larger percentage swings, because it carries both a monetary store-of-value role and heavy industrial demand in solar panels, electronics and automotive applications. Gold does not carry the industrial half. In the 2010-2011 bull run silver approached $50/oz and outperformed gold on a percentage basis; in 2013-2015, as industrial demand softened after quantitative easing ended, it fell far harder than gold on the way down. ## Gold correlation is the swing factor The fiscal-hedge leg of the thesis is a gold trade by proxy. If gold grinds higher on U.S. deficit and dollar-purchasing-power concerns, silver's high-beta character means it should outpace gold in percentage terms. If the Fed delivers more tightening than priced, or Chinese manufacturing activity weakens, the drawdown should exceed gold's. That asymmetry is the practical sizing question for anyone weighing silver exposure against a gold position. The industrial leg is where electrification enters. Silver's demand runs through solar panels, electronics and automotive applications, making it sensitive to manufacturing cycles in a way a pure safe-haven asset is not. UBS's targets assume a relatively benign industrial demand environment — an assumption that weakening Chinese factory data would directly challenge. For scale, the $64.47 print leaves silver about 24% below the $80/oz target and roughly 4% below the $70/oz December 2026 level. The metal traded in the mid-$60s through late September, having recovered from an intraday $62.57/oz after the Fed's Sept. 16 rate decision, according to Reuters. That recovery speed is itself a data point: a market treating the hike as structurally bearish would not have clawed the ground back within days. Three variables decide whether the path holds. The Fed's trajectory beyond October is the most direct threat to the dollar-sensitive side of the thesis. Industrial demand signals across solar, electronics and Chinese manufacturing test the second pillar. Dollar strength remains the primary macro headwind for all precious metals and pressures silver's monetary appeal directly. This article is for informational purposes only and does not constitute investment advice.

Sep 23 2026, 18:33

Expedia falls 7% as Meta's Muse threatens to bypass travel booking

Expedia Group fell 7% and Airbnb dropped 6% in Wednesday morning trading while Booking Holdings sank 5%, as investors repriced the online travel agency model against Muse, the personal AI agent Meta Platforms launched on Sept. 8 that can search, compare and complete bookings on a user's behalf. The selling spread across the travel complex rather than concentrating in any single name, a pattern consistent with a business-model repricing rather than a company-specific miss. Expedia's decline was the sharpest of the three, followed by Airbnb and then Booking Holdings, the largest of the group by bookings volume. All three trade on the Nasdaq. "An agent that owns the customer conversation owns the take rate," said Priya Mehta, an equity market structure analyst who tracks fund flows and positioning. "What the market is doing today is marking down the probability that the aggregator stays in the middle of the transaction." The move is the first time equity investors have put a price on agentic AI's threat to travel intermediation. Online travel agencies earn their revenue as a percentage of gross bookings — a take rate that exists because consumers historically needed a single place to compare hundreds of airlines, hotels and rental suppliers. Muse collapses that comparison step into a conversational request. Meta has roughly 3.6 billion daily users across Facebook, Instagram, WhatsApp and Messenger, and Muse can be promoted inside those surfaces without Meta paying to acquire each new customer, according to Forbes. Meta shares added close to $200 billion in market value in the weeks after the launch, including an 11% single-session jump, as investors began treating Muse as the consumer product that justifies the company's AI spending. Meta reported second-quarter revenue of $60.8 billion, up 28%, with an operating margin of 31%, and guided to 2026 capital expenditures of $130 billion to $145 billion. ## The cost of a completed booking is the number nobody has The bull case for travel agencies rests on a detail Meta has not resolved. Reuters reported that Meta is testing a "human concierge" feature in which contractors handle some Muse calls, offered to half of Meta's employees on an opt-out basis. Meta describes the trial as a way to study safety and privacy before a wider release. That matters for the disintermediation thesis because it determines whether Muse is a software platform with near-zero marginal cost per booking or a service business with labor attached. Simple requests — writing an email, finding a restaurant, comparing two flights — should automate quickly. Disputing a hotel charge, rebooking a missed connection or cancelling a subscription a provider would rather keep involve negotiation and counterparties with no incentive to cooperate. Someone also has to absorb the loss when an agent books the wrong date. Forbes contributor Jim Osman flagged the same gap, noting that customers paying $100 a month would likely be the heaviest users, making the most valuable subscribers potentially the most expensive to serve. The metric that would settle the question, he wrote, is the cost of a successfully completed task — a figure that captures computing expense, the share of jobs finished without human help, and the cost of fixing mistakes. Merchant acceptance is the second unresolved variable. Shopify has welcomed Muse and added Shop Pay, treating the agent as another channel to its merchants. Amazon has banned Muse from buying on its site, citing concerns about unlawful activity, privacy and user experience. Meta cannot compel the commercial internet to accept its agent, and revenue-sharing terms with airlines, hotel chains and payment providers will shape the eventual economics. ## Positioning unwind meets a structural question Wednesday's declines exceed the threshold that typically separates routine sector rotation from a positioning event. A single-session drop of 5% or more in three of the largest travel platforms simultaneously points to crowded longs being trimmed rather than to any change in near-term bookings, which no company has revised. The broader repricing is not confined to travel. Investors have spent 2026 shifting value from service intermediaries toward the platforms that own AI distribution, and Meta is the clearest beneficiary of that rotation given its balance sheet and existing advertising machinery. Meta can fund a long learning period for Muse out of ad revenue in a way no standalone travel or AI startup could. What would reverse the travel selloff is evidence that Muse's cost per completed booking stays high, or that suppliers refuse to grant it inventory access on workable terms. What would confirm it is a disclosed cost-per-task figure that falls quarter over quarter while paid conversions rise. Meta has not published either. Until it does, the market is pricing a probability, not a result — and the next hard data point for the travel names is their own quarterly bookings and take-rate disclosures. This article is for informational purposes only and does not constitute investment advice.